background
antivir
therapi
novel
coronaviru
caus
global
pandem
respiratori
ill
call
still
lack
studi
name
elacoi
exploratori
random
control
trial
assess
efficaci
safeti
lopinavirritonavir
lpvr
arbidol
monotherapi
treat
patient
mildmoder
find
studi
success
enrol
patient
mildmoder
randomli
assign
receiv
lpvr
arbidol
antivir
medic
control
baselin
characterist
three
group
compar
primari
endpoint
averag
time
positivetoneg
convers
nucleic
acid
convers
rate
day
similar
group
p
differ
group
secondari
endpoint
rate
antipyresi
cough
allevi
improv
chest
ct
day
p
day
eight
patient
lpvr
group
arbidol
group
control
group
show
deterior
clinic
statu
moder
severecrit
p
overal
patient
lpvr
group
arbidol
group
experienc
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
sinc
decemb
novel
coronaviru
diseas
rapidli
spread
throughout
world
outbreak
countri
region
pathogen
organ
respons
identifi
term
sever
acut
respiratori
syndrom
coronaviru
previous
name
novel
coronaviru
belong
famili
virus
respons
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
world
health
organ
declar
public
health
emerg
intern
concern
character
outbreak
pandem
march
march
st
confirm
case
death
case
document
global
despit
rapid
global
spread
littl
known
pathogenesi
viru
infecti
host
even
wors
vaccin
specif
antivir
drug
demonstr
efficaci
prevent
treatment
led
great
difficulti
control
epidem
decreas
mortal
rate
inhibitor
usual
combin
ritonavir
inhibit
cytochrom
order
increas
halflif
lopinavir
past
year
lpvr
proven
good
efficaci
limit
side
effect
treat
lopinavir
report
antivir
activ
merscov
vero
cell
concentr
caus
reduct
replic
addit
despit
lack
valid
estim
efficaci
combin
lpvr
associ
significantli
fewer
advers
clinic
outcom
acut
respiratori
distress
syndrom
death
patient
sar
compar
ribavirin
alon
histor
control
versu
p
day
onset
symptom
thu
base
vitro
test
previou
clinic
trial
demonstr
efficaci
coronavirus
lpvr
regard
option
treat
arbidol
haemagglutinin
inhibitor
effect
block
fusion
influenza
viru
host
cell
addit
also
induc
immun
system
produc
endogen
interferon
viru
replic
enhanc
phagocyt
function
macrophag
activ
natur
killer
cell
arbidol
report
effect
strain
influenza
virus
b
c
especi
influenza
virus
safe
side
effect
arbidol
also
shown
direct
antivir
effect
inhibit
replic
sar
viru
vitro
despit
preliminari
evid
actual
clinic
efficaci
lpvr
arbidol
unknown
therefor
urgent
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
need
random
clinic
trial
rct
evalu
efficaci
advers
outcom
lpvr
arbidol
treat
guangzhou
eighth
peopl
hospit
design
hospit
treatment
patient
patient
confirm
guangzhou
hospit
facil
report
exploratori
random
control
studi
elacoi
hospit
aim
provid
preliminari
evalu
efficaci
safeti
monotherapi
lpvr
arbidol
treatment
patient
mildmoder
inform
request
resourc
reagent
direct
fulfil
lead
contact
linghua
li
llheliza
studi
gener
new
uniqu
reagent
gener
new
dataset
elacoi
singlecent
random
control
trial
conduct
guangzhou
eighth
peopl
hospit
preliminarili
investig
efficaci
lpvr
arbidol
treat
patient
empir
exploratori
studi
initi
design
enrol
patient
base
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
estim
number
patient
admit
hospit
ultim
recruit
patient
randomli
assign
group
follow
group
lpvr
group
patient
administ
lopinavir
boost
ritonavir
oral
administ
twice
daili
mg
time
day
group
b
arbidol
group
patient
given
arbidol
oral
administ
three
time
daili
day
group
c
control
group
patient
given
antivir
therapi
three
group
follow
day
three
group
treat
support
care
effect
oxygen
therapi
need
antivir
treatment
discontinu
patient
treat
day
test
neg
nucleic
acid
two
consecut
test
separ
hour
discharg
hospit
intoler
side
effect
particip
met
follow
inclus
criteria
age
year
infect
confirm
realtim
pcr
rtpcr
pharyng
swab
mild
clinic
statu
defin
mild
clinic
symptom
sign
pneumonia
imag
moder
clinic
statu
defin
fever
respiratori
symptom
pneumonia
imag
follow
lab
find
creatinin
creatinin
clearanc
rate
egfr
aspart
aminotransferas
ast
alanin
aminotransferas
alt
uln
total
bilirubin
tbil
uln
willing
particip
studi
provid
inform
consent
patient
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
exclud
base
follow
criteria
known
suspect
allerg
lpvr
arbidol
sever
nausea
vomit
diarrhea
complaint
affect
oral
intak
absorpt
digest
tract
take
drug
may
interact
lpvr
arbidol
seriou
underli
diseas
includ
limit
heart
lung
kidney
diseas
liver
malfunct
mental
ill
affect
treatment
complianc
complic
pancreat
hemophilia
prior
trial
pregnant
lactat
women
suspect
confirm
histori
alcohol
substanc
use
disord
particip
drug
trial
within
past
month
deem
otherwis
unsuit
studi
research
initi
trial
protocol
approv
ethic
committe
guangzhou
eighth
peopl
hospit
approv
regist
clinicaltrialsgov
ethic
committe
agre
set
control
group
owe
lack
reliabl
evid
benefit
present
antivir
regimen
treat
trial
also
perform
accord
intern
confer
harmon
guidelin
good
clinic
practic
written
inform
consent
obtain
screen
patient
fulli
understood
mean
trial
potenti
risk
involv
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
elig
particip
assign
random
number
alloc
one
treatment
group
random
number
computergener
alloc
conceal
achiev
use
central
webbas
random
system
particip
identifi
hospit
number
enter
alloc
reveal
random
number
use
case
report
form
crf
page
studi
blind
particip
physician
radiologist
review
data
radiolog
imag
openlabel
clinician
recruit
patient
research
staff
authorfund
grant
medrxiv
licens
display
preprint
perpetu
pcr
primer
probe
set
target
fam
report
n
vic
report
gene
separ
ad
reaction
posit
neg
control
includ
batch
sampl
consid
posit
either
set
gave
reliabl
signal
primari
outcom
time
positivetoneg
convers
nucleic
acid
initi
treatment
day
enrol
day
first
day
treatment
secondari
outcom
includ
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
specimen
pharyng
swab
test
everi
day
neg
convers
nucleic
acid
defin
neg
detect
nucleic
acid
two
consecut
instanc
separ
hour
criteria
chest
ct
improv
includ
new
exud
lesion
decreas
size
exud
lesion
decreas
densiti
lesion
particip
monitor
advers
event
safeti
outcom
assess
seriou
advers
event
report
unexpect
medic
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
occurr
result
death
prolong
hospit
persist
signific
disabl
incapac
judg
causal
relat
studi
intervent
would
report
seriou
advers
event
institut
review
board
potenti
advers
event
studi
defin
follow
anaphylaxi
elev
alt
ast
upper
normal
limit
elev
tbil
upper
normal
limit
acut
pancreat
diarrhea
aim
studi
explor
efficaci
safeti
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
patient
randomli
assign
receiv
lpvr
arbidol
control
patient
follow
day
authorfund
grant
medrxiv
licens
display
preprint
perpetu
admiss
laboratori
paramet
alanin
aminotransferas
alt
aspart
aminotransferas
ast
total
bilirubin
tbil
creatinin
normal
patient
start
antivir
treatment
laboratori
paramet
includ
white
blood
cell
count
lymphocyt
count
neutrophil
count
creactiv
protein
level
procalcitonin
level
show
signific
differ
three
group
p
studi
period
six
patient
use
gamma
globulin
g
day
day
use
glucocorticoid
methylprednisolon
mg
day
day
receiv
oxygen
suppli
therapi
usag
percentag
support
treatment
show
statist
differ
three
group
respect
authorfund
grant
medrxiv
licens
display
preprint
perpetu
lpvr
group
arbidol
group
control
group
without
signific
statist
differ
p
tabl
followup
cumul
incid
positivetoneg
convers
nucleic
acid
pharyng
swab
show
statist
differ
three
group
figur
respect
secondari
outcom
rate
antipyresi
rate
cough
resolut
rate
improv
chest
ct
imag
day
show
statist
differ
three
group
p
followup
period
patient
lpvr
group
experienc
advers
event
includ
diarrhea
loss
appetit
elev
alt
normal
limit
addit
patient
arbidol
group
experienc
advers
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
authorfund
grant
medrxiv
licens
display
preprint
perpetu
case
achiev
positivetoneg
convers
nucleic
acid
day
respect
day
followup
patient
improv
chest
ct
imag
followup
endpoint
day
patient
discharg
hospit
one
case
still
hospit
death
occur
sever
clinic
studi
report
treatment
larg
number
patient
antivir
antibiot
therapi
howev
specif
medic
proven
effect
suppress
elimin
infect
reduc
complic
mortal
sever
ongo
clinic
drug
trial
regist
chines
clinic
trial
registri
although
epidem
within
china
larg
control
epidem
countri
becom
increasingli
sever
therefor
extrem
import
find
specif
anti
drug
learn
experi
chines
health
provid
studi
design
empir
explor
intend
recruit
adult
patient
hospit
mildmoder
howev
patient
involv
studi
reason
previous
mention
random
patient
assign
receiv
lpvr
arbidol
antivir
medic
control
result
show
lpvr
arbidol
shorten
time
positivetoneg
convers
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
shanghai
observ
patient
find
effect
lpvr
arbidol
reliev
symptom
acceler
viru
clearanc
treatment
day
despit
small
sampl
size
studi
also
suggest
monotherapi
lpvr
arbidol
might
improv
clinic
outcom
treat
mildmoder
studi
period
total
patient
progress
severecrit
clinic
statu
includ
receiv
lpvr
receiv
arbidol
control
group
indic
diseas
condit
could
still
worsen
even
hospit
thu
urgent
demand
rigor
observ
ill
care
fortun
endpoint
studi
twelv
patient
discharg
hospit
recoveri
one
patient
remain
hospit
albeit
signific
clinic
improv
give
us
confid
even
absenc
specif
antivir
drug
vast
major
patient
severecrit
clinic
statu
still
recov
comprehens
treatment
studi
without
limit
first
recogn
sampl
size
small
second
studi
enrol
sever
critic
ill
patient
patient
increas
risk
poor
outcom
mani
comorbid
conduct
one
center
third
studi
complet
blind
possibl
influenc
outcom
extent
continu
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
follow
patient
evalu
longterm
prognosi
nevertheless
prospect
random
control
trial
studi
could
still
provid
meaning
suggest
proper
applic
lpvr
arbidol
treatment
conclus
studi
found
lpvr
arbidol
monotherapi
present
littl
benefit
improv
clinic
outcom
hospit
patient
mildmoder
beyond
symptomat
support
care
caus
instead
advers
event
work
need
confirm
result
chen
wenxin
hong
guangm
xiao
contribut
conduct
studi
collect
data
declar
compet
interest
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
hypertens
lpvr
group
one
patient
coronari
heart
diseas
hypertens
chronic
liver
diseas
arbidol
group
one
patient
coronari
heart
diseas
hypertens
chronic
liver
diseas
diabet
chronic
liver
diseas
control
group
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
